Page 48 - Sohini Das

USFDA observations in 2022 focus on ancillary infra, written procedures

45% observations in 2022 around unavailability of written procedures and facility maintenance, ancillary infrastructure

Lupin likely to demerge its active pharmaceutical ingredients business

As such the API business contributes around 7 percent to Lupin's overall turnover

We want to become the no. 1 diagnostics provider in the world: Mylab MD

'The Mylab ecosystem is capable of providing solutions'

WHO investigating more syrups, drug samples; list of alerts may expand

The WHO director-general issued a call to action in January to implore all member states to increase their surveillance and testing efforts because people are 'needlessly being put at risk'

Instead of cough syrup testing, need to go for root-cause analysis: Bhaskar

Pharmaceutical exports from India have come under the scanner after sporadic incidents of contaminated or substandard medicines

DRL enters trade generics, aims to be among top five players in market

Exploring strategic collaborations in the country, says pharma firm

Self-regulatory body for pharma industry on cards: Mansukh Mandaviya

Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants

Truck operators raise heat over govt's air-conditioned cabin proposal

But commercial vehicle OEMs welcome the move, saying demand for AC trucks is already going up

Will launch 10 vehicles this year: Mercedes-Benz India CEO Santosh Iyer

'And a majority will be in the top-end vehicle range', says Santosh Iyer

Fewer Indian pharma plants get US FDA action notice in 2023, so far

6 per cent of inspections in first 6 months of CY23 resulted in OAI status

Possible to make new Covid strain vax in 100 days: Gennova BioPharma

Co gets nod for Omicron booster of its mRNA vaccine

Nearly half of Ukraine-returned students have shifted to other countries

10% students go back to Ukraine; nearly 50% shift to countries like Russia, Georgia, Uzbekistan

Novo Nordisk to double India manufacturing, bring new drugs by 2025

Plans to bring new drugs by 2025 into the country, which is part of all its global clinical trials

2 more Indian drugmakers under lens in Nigeria for 'contamination'

Nigerian health agency flags off paracetamol, cough syrup

Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data

Focus on profitability, and less options other reasons behind the slowdown seen till May this year

US drug shortage a shot in the arm for Indian pharmaceutical companies

Indian pharma to benefit from exit of a few bankrupt generic US firms

Isuzu may sell 44% stake in India unit as it exits low-profit businesses

Japanese firm, whose stake is valued at Rs 734 cr, is talking to several potential investors including JBM Auto, a media report said on Friday

Health Ministry planning to prepare National Action Plan on AMR 2.0

AMR has been identified by the World Health Organization (WHO) as one of the significant threats to global health

Ignition of change in electric vehicle battery ecosystem in India

Manufacturers are gradually emerging in a business dominated by assembly operations

Mahindra & Mahindra, Hinduja join race to buy MG Motor India stake

SAIC Motor-owned firm seeks EoIs, but no binding offers yet